Kimia Bioscien. — 360° view

Kimia Bioscien, a company in the Pharmaceuticals industry, reported revenue of ₹27 crore and net profit of ₹2.39 crore for the September 2026 quarter.

Kimia Bioscien. (BSE: KIMIABL) closed at ₹30.41 on 20 Nov 2026, down 10.8% over the past year. Its market capitalisation is ₹144 crore and it trades at 16.8 times earnings.

Share price
₹30.41 (20 Nov 2026)
Market cap
₹144 Cr (20 Nov 2026)
P/E
16.81 (20 Nov 2026)
Revenue
₹27 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
25.1% (FY26)
ROE
53.7% (FY26)
Book value
₹4.32 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹43.28 / ₹23.20 (20 Nov 2026)
1-year return
-10.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: KIMIABL

Incorporated in 1993, Kimia Biosciences Ltd is in the business of manufacturing and sale pharmaceutical products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.